ADMA Biologics, Inc. Annual report pursuant to section 13 and 15(d)

Annual report pursuant to section 13 and 15(d)

10. STOCK OPTIONS (Tables)

10. STOCK OPTIONS (Tables)

12 Months Ended

Dec. 31, 2012

	Year Ended December 31, 2012				Year Ended December 31, 2011
	Shares		Weighted Average Exercise Price		Shares		Weighted Average Exercise Price
Outstanding at beginning of period		83,378	$	3.33		83,378	$	3.33
Forfeited		-	$	-		-		-
Granted		506,559	$	9.60		-		-
Outstanding at end of period and expected to vest		589,937	$	8.71		83,378	$	3.33
Options exercisable		175,022	$	6.67		80,282	$	3.38
Weighted-average fair value of options granted during the period			$	6.82			$	-

Stock-based compensation expense

	2012		2011
Research and development	$	101,606	$	891
General and administrative		525,181		22,056
Total stock-based compensation expense	$	626,787	$	22,947

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details